OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850
UNITED STATES
Phone: +1-888-267-4436
Fax: +1-301-340-8606
techsupport@origene.com

OriGene Technologies GmbH
Schillerstr. 5
32052 Herford
GERMANY
Phone: +49-5221-34606-0
Fax: +49-5221-34606-11
info-de@origene.com

AM00382SU-N Monoclonal Antibody to Progesterone receptor - Supernatant

Alternate names: NR3C3, Nuclear Receptor Subfamily 3 Group C Member 3, PGR, PR

Quantity: 0.5 ml

Background: The progesterone receptor is an intracellular steroid receptor that specifically binds progesterone. Expressed by a single gene (chromosome 11q22), it has two main forms, A and B, that differ in their molecular weight. It has been proposed that expression of PR determination indicates a responsive estrogen receptor (ER) pathway, and therefore, may predict likely response to endocrine therapy in human breast cancer. A number of studies have shown that PR determination provides supplementary information to ER, in predicting response to endocrine therapy as well as estimating survival. PR has proved superior to ER as a prognostic indicator in some studies.

Uniprot ID: P06401

NCBI: NP_000917.3

GeneID: 5241

Host / Isotype: Rabbit / IgG

Clone: BV7

Immunogen: Synthetic cyclic peptide from the antigen's c-terminus

Format: **State:** Liquid cell culture supernatant
Buffer System: Diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative

Applications: Immunohistochemistry on paraffin sections (1:25 to 1:100 in an ABC method), requires high temperature antigen unmasking with 10 mM citrate buffer, pH 6.0 prior to immunostaining; incubation period of 30-60 minutes at room temperature.
Positive control: Breast carcinoma.
Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Specificity: This antibody detects Progesterone Receptor.
Species: Human.
Other species not tested.

Add. Information: Cellular Localization: Nuclear

Storage: Store the antibody at 2 - 8 °C.
Shelf life: one year from despatch.

General Readings:
1. Clarke CL et al Endocrinology 1987; 121: 1123-32.
2. Feil PD et al Endocrinology 1988; 123: 2506-13,
3. Dabbs DJ et al. Diagnostic Immunohistochemistry 2002 Churchill Livingstone.
4. Kell DL et al. Applied Immunohistochemistry 1993; 1(4): 275-81.
5. Leong ASY et al. Applied Immunohistochemistry 1993; 1(4): 282-288.
6. Tesch M et al. Am J Clin Pathol 1993; 99:8-1.